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Abstract
The purpose of this scholarly project was to evaluate an evidence-based quality
improvement program implemented in 2016 in a clinical practice setting to curtail
overprescribing of opioids for noncancer pain management. In 2001, the National
Pharmaceutical Council and The Joint Commission on Accreditation and Hospital
Accreditation initiated a standard of practice for opioid use in noncancer pain
management that resulted in opioid overprescribing and a 200% increase in opioidrelated deaths and incalculable societal costs. Primary care providers including nurse
practitioners issue the greatest number of opioid prescriptions; therefore, to address the
problem of opioid overprescribing, the 2016 Centers for Disease Control and Prevention
guidelines for opioid administration were implemented as a quality improvement
program in a primary care setting with 10 providers. Lewin’s change model was the
vehicle for change and included an ongoing audit developed for tracking provider
prescribing rates. The project sought to determine if adoption of the opioid administration
guidelines reduced the prescribing rates in a clinical practice setting and thereby justify
expanding the program to other primary clinic sites. A pre- post-single group comparison
was conducted of prescribing rates from May 15, 2015 prior to implementing the
guidelines and December 19, 2016 after the guidelines were in place. Analysis from t
tests indicated a 41% (p < .01) reduction in prescribing rates. The project promotes
positive social change through the decreased individual and societal cost of opioid-related
deaths.
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Section 1: Overview of the Project
Introduction
My aim in this project was to evaluate a quality improvement program that had
the potential to address the well-documented problem of opioid overprescribing in
primary care practice resulting in poor patient outcomes (Manchikanti et al., 2012;
Paulozzi, Mack, & Hockenberry, 2014). The literature review method that I chose to
guide the program included relevant literature identified through searches of MEDLINE,
Agency for Health Research Quality (AHRQ), Health Resources and Services
Administration (HRSA), Google Scholar, and PubMed. Also included were required and
recommended readings from the Walden University Doctorate of Nursing Practice
Program. I researched the terms quality improvement, opioids, opioid addiction,
overprescribing, opioid epidemic, opioid guidelines, and opioid recommendations.
The program incorporated a multidisciplinary team of stakeholders to apply a
systematic approach to a practice change (HRSA, 2016; Joshi, 2014). A team-based
approach helps organizations to achieve significant and lasting quality improvements
(HRSA, 2016). This program was designed to effect a permanent change in the approach
to the treatment of pain. The organization anticipated that the program would have
ongoing quality improvement support through peer review and monitoring systems to
ensure that the change is implemented and remains in effect after the initial
implementation phases (AAFP, 2016; Joshi, 2014). In Section 1 of this project, I cover
the problem of opioid misuse, the purpose of the program, the nature of the program, the
program’s significance, and a summary.
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The Problem
My aim in this project was to determine if this implemented evidence-based
program would curtail opioid overprescribing in primary care. I used the Centers for
Disease Control and Prevention [CDC] (CDC, 2016a) clinical guidelines as the main
instrument of change for the program. Advanced practice nurses, as primary care
providers (PCPs), are equipped to take on leadership roles in countering the current
opioid overprescribing trend through the application of evidence-based practice
guidelines (American Association of Colleges of Nursing, 2006). Prescription opioid
disorders are a significant national public health problem as well as a patient safety
concern (CDC, 2015a). CDC (2015b) national vital statistics have indicated that, since
2001, the number of opioid prescriptions for the treatment of noncancer, nonpalliative
care pain has increased exponentially (CDC, 2016b; Manchikanti et al., 2012).
Unfortunately, along with this increase in opioid use for the treatment of noncancer pain,
the prevalence of opioid misuse, abuse, disorders, diversion, and deaths has grown (CDC,
2015a; Health and Human Services [HHS], 2016). This alarming trend has mandated the
attention of the CDC, as well as other governmental and health care organizations (Time
Inc., 2016; White House Statements and Releases, 2016). This problem has now
advanced to the stage of an epidemic (CDC, 2016b).
Given that a 200% increase in opioid related deaths was registered between 2000
and 2014, there was a need to evaluate and modify the way that PCPs treat pain (see
Figure 1). The reversal of this trend required a new approach to the treatment of pain due
to negative patient outcomes (CDC, 2015a, 2015b). The escalating use of therapeutic
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opioids reflects a lack of understanding of the addictive nature of this substance
(Manchikanti et al., 2012); National Pharmaceutical Council [NPC], 2001). Dependence
can occur in as little as 1 week (NPC, 2001). Thus, my aim in this project was to evaluate
this informed practice change through utilizing evidence-based guidelines directed
toward PCPs and the way they treat pain.
Figure
Figure 11
Drug
Drug Overdose
Overdose Deaths
Deaths Involving
Involving Opioids
Opioids by
by type
type of
of Opioid
Opioid
2000
2000 to
to 2014
2014

Reproduced from Centers for Disease Control. Multiple cause of death
data on CDC WONDER. Atlanta, GA: US Department of Health and
Human Services, CDC. Accessed 12/1/2016 from http://wonder.cdc.gov/
mcd.html

Figure 1. Drug overdose deaths involving opioids by type of opioid 2000−2014 (with
permissions).
To address the problem of opioid prescribing locally, the State of California
passed legislation requiring health care providers to access the state database to obtain a
patient drug monitoring report prior to prescribing any Schedule II drugs (American
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Insurance Association [AIA], 2016). This online database alerts prescribers of patients
attempting to “‘doctor shop’ in order to obtain controlled substances” (AIA, 2016). The
governor of California responded to the epidemic of opioid deaths facing the State of
California and the nation (AIA, 2016; Harris, 2015). This mandate is one of the
recommendations found in the CDC (2016a) guidelines.
In addition, PCPs have now come under legal jeopardy for opioid prescribing
practices (CDC, 2016b). There may be legal implications for failure to adhere to
responsible practice guidelines. The implications of not addressing the practice problem
include the potential for governmental and patient litigation (Gerber, Girion, & Queally,
2015; McMullen & Howie, 2011). Once a standard has been established by a credible and
validated oversight agency, the potential for litigation is introduced. Such litigation has
already occurred in the State of California, whereby a physician was convicted of seconddegree murder due to reckless opioid prescribing practices (Gerber et al., 2015). The legal
and financial implications of operating below an established industry standard were
established with this precedent. Suboptimal care in light of the new standard may be
viewed as malpractice (Mosby, 2009).
The societal costs of prescription opioid dependence, abuse, and misuse have
been evaluated and are grouped into three categories: health care, workplace, and
criminal justice (Birnbaum et al., 2011). According to Birnbaum et al. (2011),
Total US societal costs of prescription opioid abuse were estimated at $55.7
billion in 2007 (USD in 2009). Workplace costs accounted for $25.6 billion
(46%), health care costs accounted for $25.0 billion (45%), and criminal justice
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costs accounted for $5.1 billion (9%). Workplace costs were driven by lost
earnings from premature death ($11.2 billion) and reduced compensation/lost
employment ($7.9 billion). Health care costs consisted primarily of excess
medical and prescription costs ($23.7 billion). Criminal justice costs were largely
comprised of correctional facility ($2.3 billion) and police costs ($1.5 billion).
(pg.1)
These costs were anticipated to continue to rise with increasing prescribing rates
(Birnbaum et al., 2011). Consequently, I sought to evaluate a program aiming to address
the practice challenge of excessive opioid prescribing and to advance patient safety and
health care delivery quality in primary care (AACN, 2006). I evaluated the quality
improvement program through the capture of prescribing patterns obtained using
information technology (IT) as described by HRSA (2016). By using prescribing rates
sourced from the electronic health records (EHRs) or billing records, the process was not
only more efficient but theoretically proved to be more accurate than manual counting
methods (HRSA, 2016). This method provided evidence by capturing the prescribing
rates obtained before and after the program implementation. This technique assisted in
evaluating the program’s ability to curtail the overprescribing of opioids for noncancer
pain.
Purpose
The purpose of the project was to evaluate a program that addresses a primary
care practice gap. This gap is proposed to stem from the underuse of the CDC opioid
prescribing guidelines resulting in overprescribing. PCPs express concerns regarding
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opioid pain medication misuse. However, they emphasize that they are overwhelmed by
treating patients presenting with chronic pain, as well as cite concerns with addiction and
report being inadequately prepared for prescribing opioids (Jamison, Sheehan, Scanlan,
Matthews, & Ross, 2014). According to the CDC (2015b), PCPs are prescribing opioids
at increasing rates and are not adhering to current evidence-based clinical guidelines
(CDC, 2016b; Cheatle, Comer, Wunsch, Skoufalos, & Reddy, 2014). To bridge the
current practice gap, this program was based on the CDC (2016a) standardized guidelines
and clinic policy, and it employed an evaluation tool to monitor implementation of the
Figure 2
Primary Care Prescribing Criteria
1. Patient risk assessment. Clinicians should consider opioid therapy only if the expected
benefits for both pain and function are anticipated to outweigh the risks to the patient.
Clinicians should evaluate the risk factors for opioid-related harms. Screening or risk
assessment tools to identify patients at higher risk for misuse or abuse of opioids are
recommended.
2. Obtain a patient/provider pain contract. This contract will include the patient and provider
criteria for use, discontinuance, and disclosures regarding the addictive nature of the substance.
Experts agree those are essential elements to communicate to patients before starting and
periodically during opioid therapy include realistic expected benefits, common and serious
harms, and expectations for clinician and patient responsibilities to mitigate risks of opioid
therapy.
3. Obtain initial and random encounters drug screens. Experts agree that prior to starting
opioids, and periodically during opioid therapy, clinicians should use urine drug testing to
assess for the use of the prescribed opioids as well as other controlled substances. This
includes illicit drugs that increase risk for overdose when combined with opioids, including
non-prescribed opioids, benzodiazepines, and heroin.
4. Obtaining a CURES or patient drug monitoring report to assess opioid use patterns.
Clinicians should review the patient’s history of controlled substance prescriptions using state
prescription drug monitoring program (PDMP) data to determine whether or not the patient is
receiving opioid dosages or dangerous combinations that put him or her at high risk for
overdose. Clinicians should review PDMP data when starting opioid therapy for chronic pain
and periodically during opioid therapy for chronic pain, ranging from every prescription to
every 3 months.
5. Discussing the expected duration of treatment and outcomes. When opioids are used for
acute pain, clinicians should prescribe the lowest effective dose of immediate-release opioids
and should prescribe no greater quantity than needed for the expected duration of pain severe
enough to require opioids. Three days or less will often be sufficient; more than seven days will
rarely be needed.
Reproduced from Primary Care Prescribing Criteria Centers for Disease Control, 2016 CDC
Guideline for prescribing opioids for chronic pain. MMWR: United States. Accessed 12/1/
2016 http://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm
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practice change. To determine the effectiveness of the program implemented at the
practice site, I used the evaluation tool to assess for the continued application of the CDC
guidelines in the primary care practice (See Figure 2 Prescribing Criteria). The findings
revealed that this program assisted in curtailing prescribing rates by this approach to
bridging the practice gap (CDC, 2016b). The CDC has issued 12 recommendations for
safe opioid prescribing (CDC, 2016a).
The purpose of this scholarly project was to evaluate a quality improvement
program and assess its potential to address the current practice gap of overprescribing in a
primary care practice in central California. The aim of implementing this program was to
address the growing problems of opioid abuse and dependence, along with related deaths
and disorders affecting the practice and this primary care community (CDC, 2016a; HHS,
2016). As a quality improvement initiative, the current program was initiated to assist the
organization in meeting the state mandates and applying the CDC recommendations for
the safe prescribing of opioids (AIA, 2016; CDC, 2016a; Harris, 2015). Since July 1,
2016, all providers in the State of California have been required to enroll in the State
Drug Monitoring Program (Harris, 2015). In addition, all providers are now required to
obtain a Patient Drug Monitoring Report (CURES), prior to prescribing opioids (AIA,
2016).
The risk manager at the facility where this doctoral project took place has
identified the need for a practice change due to an increase in the number of drug-seeking
patients, increased opioid-related patient morbidity and mortality, as well as
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organizational liability. There have been threats of litigation from the families of patients
who received and became addicted to opioids.
Chart audits revealed a marked discrepancy between evidence-based CDC safe
opioid prescribing recommendations and the current prescribing practices in this primary
care setting (Cheatle et al., 2014; Lasser et al., 2014). The prescribing practices in the
local primary care settings were consistent with the CDC findings, whereby primary care
clinicians overprescribe opioids to manage pain, including chronic pain (CDC, 2016b;
Cheatle et al., 2014; Chou, 2016). As in many similar primary care settings, few of the
clinicians in the local clinic where this project took place adhere to the current CDC
clinical guidelines or recommendations for safe opioid prescribing (CDC, 2016b). This
was evidenced through peer review chart audits, which confirmed existence of a practice
gap with poor patient outcomes (CDC, 2016a).
Nature of the Project
This project was the evaluation of an evidence-based systematic primary care
quality improvement program. I developed it according to a problem-solving evaluation
design as outlined by Grove, Burns, and Gray (2014). The particular problem of opioid
overprescribing in primary care practice and the underuse of clinical guidelines resulted
in a practice gap that was addressed by the program. According to Groves et al. (2014),
“Evaluation projects are conducted with minimal application of the rigor and control
required with research” (p. 82). This project involved comparing the appropriate indices,
retrieved from the EHRs, before and after the use of the CDC (2016a) clinical prescribing
recommendations. The postintervention indices were compared with the preintervention
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indices to determine the effectiveness of the program in terms of measurable behavioral
changes that influenced the provider prescribing rates. My goal in this project was to
assess the program’s ability to bridge the practice gap through measuring and comparing
the prescribing rates.
Given that PCPs are the leading prescribers of opioids, they were the population
targeted for participation in the program (CDC, 2016b). Moreover, as this facility is the
second largest primary care practice in central California, the results of the evaluation
project may hold significance for other health care providers. As a problem-solving
project, the findings yielded by the program evaluation will be relevant to this specific
health care agency. Essentially, the program was an attempt to address the prescription
opioid problem with standardized evidence-based practice (Grove et al., 2014). The risk
manager at this facility had identified overprescribing as an organizational problem and
has sought to bring its PCPs in line with the new CDC standards of care. Whether this
program could achieve the goal was in question.
PCPs are estimated to prescribe more than 50% of all opioid prescriptions
nationally (CDC, 2016b). Consequently, they have the greatest influence over the sheer
volume of prescriptions being written for the treatment of pain. Hence, interventions to
address the problem of overprescribing needed to be inclusive of this stakeholder group.
In fact, in 2012, health care providers issued 259 million opioid prescriptions (Paulozzi et
al., 2014). Given this information, the necessity of effecting change in prescribing
practices is evident (Liu, 2013). The purpose of this project was to evaluate a program
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incorporating evidence-based change to alter the practice gap in opioid prescribing in this
primary care practice setting.
The First Phase of Program: Methodology
The first phase of the program began with unfreezing the current prescribing
patterns among the PCPs within the Family Medical Group (Lewin, 2008). Unfreezing
was supported through peer review (see Appendix A), the evidence-based guidelines,
policy change (see Appendix B), and identified prescribing rates. As a part of the
program, the risk manager was included and presented deidentified case studies for
providers to review and assess. The multidisciplinary process of unfreezing was evidence
based and incorporated literature relevant to and supporting the need for change. Upon
project approval, the quality improvement (QI) manager collected baseline indices for
this period from the EHR. These indices related to opioid prescribing rates for PCPs
preprogram. I extrapolated the EHR data retrospectively for the project purposes to
evaluate the preprogram prescribing patterns and rates.
This phase included a PowerPoint presentation that addressed PCPs and
stakeholders (see Appendix C). The presentation commenced with a summary of the old
standards as introduced by NPC & Joint Commission on Accreditation of Healthcare
Organizations (JCAHO) (2001). The program identified the basis for the current
prescribing practices as well as the reasons for the need to cease the current prescribing
trends. According to the NPC & JCAHO (2001),
This has evolved into the present stage, with the introduction of pain management
standards by JCAHO in 2000, an increased awareness of the right to pain relief,
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the support of various organizations supporting the use of opioids in large doses,
and finally, aggressive marketing by the pharmaceutical industry. (pg.1)
These positions were based on unsound science and blatant misinformation, and they
were accompanied by the dangerous assumptions that opioids are highly effective and
safe and devoid of adverse events when prescribed by physicians (CDC, 2016a;
Manchikanti et al., 2012). This information provided the rationale and the foundation for
the inception of the problem and the current provider dilemma it has created, thus
confirming the need for change. Although providers may not have intended to initiate the
addiction process, their reliance on the old protocol for opioid prescribing has contributed
to this adverse effect (Chou, 2016; Chou et al., 2009).
To unfreeze current practices, the management deemed a punitive approach to this
practice problem inappropriate. This perspective aligned with the findings of analyses
pertaining to the influence of medical standards on this practice issue (NPC & JCAHO,
2001). To ensure greater stakeholder support for these proposed changes, full disclosure
of the inception of the problem was required for a better transition into provider
acceptance of the new recommendations (Joshi, 2014). Thus, the Just Culture Model
promoted by the American Nurses Association (2010) was applied to move from a
punitive approach to one that focuses on change. According to the American Nurses
Association (2010), as the Just Culture Model provides a better approach to problem
solving, it should be used as an alternative to a punitive system. The Just Culture Model
seeks to create an environment that encourages individuals to report mistakes and is
widely used in the aviation industry (Understand Just Culture, 2016). The aim is to better
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understand the precursors to errors to eliminate the system issues (Understand Just
Culture, 2016). Adoption of this model encourages a two-way dialog and feedback to
promote behavioral changes (Understand Just Culture, 2016).
During this phase, a forum for dialogue allowed clinicians to discuss their
attitudes regarding prescribing opioids without fear of reprisal (Joshi, 2014; Understand
Just Culture, 2016). In addition, in the unfreezing phase, open provider dialogue allows
barriers to be identified. According to Manchikanti et al. (2012), “The obstacles that must
be surmounted are primarily inappropriate prescribing patterns, which are largely based
on a lack of knowledge, perceived safety, and inaccurate belief of under-treatment of
pain” (p. ES10). This saved time during the implementation phase, as there were fewer
unidentified or unresolved barriers to impede the change implementation (Joshi, 2014).
The anticipated legal barriers for providers were addressed during this phase. The
real potential for litigation had been identified as a barrier to changing provider’s current
opioid prescribing practices (Hoffmann & Tarzian, 2003). This dialogue was especially
relevant, as providers have been successfully sued based on previous standards of care
(Hoffmann & Tarzian, 2003). Providers who were accustomed to issuing prescriptions
for controlled substances for commonly occurring noncancer pain may have resisted the
mandate to make the practice adjustments due to fear of potential litigation (Hoffmann &
Tarzian, 2003). The new precedent for ligation was presented based upon a recent case,
whereby a physician was tried and convicted of second-degree murder for
overprescribing (Gerber et al., 2015). The new practice standards have been upheld by
the legal system with this conviction (Gerber et al., 2015).
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The Second Phase Program: Data Collection
The second phase of change, as described by Lewin, involved the adoption and
application of evidence-based clinical guidelines in primary care (Lewin, 1947, 1951,
2008; McEwen & Wills, 2014). To determine whether the change occurred, an
assessment was required. The evaluation of the clinical guidelines use included a peer
review and policy implementation (see Appendix B). I evaluated five provider charts
monthly using a tool to assess provider policy adherence. The QI manager was
responsible for assigning the EHRs for the monthly peer reviews. To obtain the necessary
support from the stakeholders, it was important to engage them during all stages of care
management program development. Peer review was an effective tool for monitoring the
adoption and continuance of the practice change (AAFP, 2016; Chan, 2014). According
to the AHRQ, the target population involvement in the rudimentary phases of change is
essential for successful program design, as it helps ensure long-term support for the
program. During the implemented change process, seeking feedback from the PCPs was
necessary. Peer review served as a vehicle to provide that feedback without fear of
reprisal or ligation (AAFP, 2016). It was important to include strategies that encouraged
the involvement of stakeholders to establish collaborative relationships and promote an
ongoing two-way dialog (Joshi, 2014).
I evaluated the overprescribing rates upon practical application of the clinical
guidelines. The assessment included the extent to which prescribers used risk
stratification, pain contracts, random drug testing, patient drug monitoring reports, and
other recommended strategies prior to issuing prescriptions. This initiative also included
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assessing the number of opioid prescriptions for alterations (CDC, 2016a). When
providers consider factors other than self-reporting of pain, they are more responsible in
their prescribing practices in primary care setting (CDC, 2016a). According to the U.S.
surgeon general, self-reporting as the primary criterion for pain treatment excludes some
crucial factors that may result in addiction, such as multiple prescribers, abuse, misuse,
and diversion (Time Inc., 2016). According to the program, opioid prescribing rates
decreased once these factors were considered.
The Third Phase Program: Analysis
The third phase of refreezing, as described by Lewin (1947, 1951, 2008), involved
ongoing peer evaluation of the program implementation to operationalize the new
prescribing practice. The aim was to deter providers from returning to old prescribing
patterns. The peer review approach has been identified as an appropriate learning and
evaluation tool in the clinical setting (Chan et al., 2014). According to American
Academy of Family Practice (AAFP, 2016), an effective peer review is an essential part
of improving the quality of health care delivery (see Appendix A). Peer review, when
performed effectively, leads to improvements in the quality and safety of patient care,
while also enhancing clinical performance (Chan et al., 2014). Peer review was used
because it provided the QI Manager with the data that could be analyzed to assess the
degree to which the program was being successfully implemented (AAFP, 2016). It also
provided the medical director with the information required to direct the providers in the
quality improvement practice change (AAFP, 2016).
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Significance
This project holds significance to nursing staff as well as all primary providers by
providing insights and guidance in clinical decision making. Nurses, as a part of the
opioid overprescribing problem, take on a leadership role in providing evaluation of
a quality improvement program targeted at the problem of overprescribing in primary
care practice (ACCN, 2016; CDC, 2016a, 2016b). It remained to be determined if
the program that used the CDC clinical guidelines can curtail overprescribing when
applied in a systematic approach. The direct and positive correlation between death rates
and the opioid prescribing practices in primary care has negatively affected society
(Birnbaum et al., 2011). It remains to be determined if the trajectory may be altered with
the implementation of this program.
Summary
The opioid epidemic was created by a faulty standard of practice initiated by a
National Certifying Agency (Manchikanti et al., 2012; NPC & JCAHO, 2001). This
epidemic is currently provider driven (CDC, 2015c, 2016b). This practice has resulted in
a 200% increase in opioid-related deaths (CDC, 2015b, 2016b, 2016d). I sought to
evaluate a program that was directed toward curtailing the practice problem through
introduction of and adherence to evidence-based clinical guidelines. This program,
referred to by Joshi (2014) as a high-impact intervention program, is aimed to address a
prevalent health problem. The aim of the current project was to evaluate an implemented
systematic approach to change opioid prescribing practices based on Lewin’s change
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model, which allowed operationalizing the program in three phases (Lewin, 1951, 2008).
This systematic program was directed towards facilitating an organizational practice
delivery change to improve patient outcomes (AACN, 2006).
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Section 2: Background and Context
Introduction
The problem of opioid overprescribing has resulted in an increase in addiction,
misuse, dependence, and deaths (CDC, 2016; HHS, 2016). The CDC has developed
clinical guidelines to address this health problem and curtail opioid prescribing (CDC,
2016a). This practice problem provided the opportunity for nursing staff to take on a
leadership role in developing a systematic program and determine its effectiveness in
addressing the current opioid epidemic (AACN, 2006; CDC, 2016b). A review of
pertinent literature has revealed a practice gap, in that few providers use current clinical
guidelines when prescribing these medications (Cheatle et al., 2014; Lasser et al., 2015).
As a part of this scholarly project, I evaluated a program that incorporated the new
evidence-based CDC clinical guidelines in terms of its ability to address this practice gap
(CDC, 2016a). In the next section, I will provide an overview of the program’s
conceptual model that was previously operationalized in the phases, in addition to
delineating its relevance to nursing practice, the local background, and context, before
summarizing the discussion. The section will close with the description of my role in the
program evaluation.
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Figure 3
Conceptual Model of the effects of Clinical Guidelines in Safe Prescribing Practices

My aim in the project was to evaluate an evidence-based program implemented at
a primary care site to curtail overprescribing. An additional objective was to determine
the effectiveness of the use of clinical guidelines in addressing the problem of
overprescribing in primary care (Le Flore, 2016). Through situational relating, I was able
to establish the association of the relationships between the concepts of overprescribing
and application of the CDC clinical guidelines. The change model developed by Lewin
has served as the specific vehicle of change. Its phases included unfreezing, change, and
refreezing (Lewin, 1947, 1951, 2008; McEwen & Wills, 2014). I used this model to
operationalize the project and define its three phases, including methodology, data
collection, and analysis, respectively. The first phase involved providing the foundation
for the practice change. The primary changes were effected in the second phase through
the application of clinical guidelines. The third phase was designated to continuous
provider assessment to ensure that they did not return to the previous prescribing
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practices. I communicated the information pertinent to each of these phases to the
practitioners through a PowerPoint presentation (see Appendix C).
Relevance to Nursing Practice
The overprescribing problem exists in nursing practice, and in particular among
advanced practice nurses who furnish controlled substances. The opioid overprescribing
practice problem is not solely a physician concern. In a study conducted by Chen,
Humphreys, Shah, and Lembke (2016), the authors wrote:
The researchers examined Medicare prescription drug claims data from 2013 for
808,020 individual prescribers, including physicians, nurse practitioners,
physician assistants, and dentists. From an analysis of total claims, it was
determined that in 2013, most opioids were prescribed by healthcare providers in
family practice (15.3 million prescriptions) and internal medicine (12.8 million),
followed by nurse practitioners (4.1 million) and physician assistants (3.1
million). (p. 260)
The authors further noted, “Efforts to curtail national opioid overprescribing must address
a broad swath of prescribers to be effective” (Humphreys et al., 2016, p. 259). The onus
of the opioid crises belongs to more than one select group of practitioners.
Given that a significant number of nurse practitioners are writing opioid
prescriptions, they are compounding this problem. Consequently, they should also be
involved in any remedial initiatives (Chen et al., 2016). This practice problem presented
me with an opportunity to take on a leadership role by evaluating the implementation of
practice changes necessary to curtail overprescribing within health care organizations
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(AACN, 2006). Currently, several organizations, including the American College of
Physicians and the World Health Organization, have developed guidelines for prescribing
opioids for the treatment of pain (Chou, 2009; McMullen, 2011). Those guidelines were
attempts to curtail prescribing as well. However, this program was identified because it
used the CDC (2016a) guidelines which have its focus on PCPs.
Local Background and Context
A review of the scholarly evidence reveals the existence of a significant opioid
prescribing problem in the United States, as well as delineates some adverse
consequences for patient health and safety (CDC, 2014, 2015a, 2016a, 2016b, 2016c;
HHS, 2016; Manchikanti et al., 2012). Opioid abuse is such a serious public health
concern that it is deemed a national epidemic by the CDC (2016b) and HHS (2016). In
2015, the CDC launched the Prescription Drug Overdose: Prevention for States Program,
as a part of which $20 million was provided to all US states to support strategies aimed at
improving prescribing practices. This effort was designed as a means of preventing
prescription opioid-related deaths (White House Statements and Releases, 2016).
From 1999 to 2014, it was estimated that more than 165,000 deaths in the United
States were associated with opioid use (CDC, 2016d). Drug overdose deaths are the
leading cause of injury death in the United States (CDC, 2016b; HHS, 2016; Manchikanti
et al., 2012). According to HHS (2016), “President Obama released his first National
Drug Control Strategy, which emphasized the need for action to address opioid use
disorders and overdose, while ensuring that individuals with pain receive safe, effective
treatment” (as cited in Pratt, 2016, p. 1). The current statistics show that opioid overdose
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results in 44 deaths daily (CDC, 2016b). In 2016, the National Institute on Drug Abuse
(NIDA) also reported, “The current epidemic of prescription opioid abuse has led to
increased use of heroin, which presents similar dangers” (as cited in Pratt, 2016, p. 1).
HHS (2016) estimates indicate that 450 individuals transition from prescribed opioids to
heroin daily. Such high prevalence of opioid-related disorders is causing fracturing of
homes, communities, and societies, resulting in billions of dollars lost in productivity
(Birnbaum et al., 2011). In 2014, more than 10,500 individuals died from heroin overdose
(HHS, 2016).
Since 1999, the amount of opioid prescription drugs prescribed and sold in the
United States has nearly quadrupled (Manchikanti et al., 2012). According to Agarin,
Trescot, Agarin, Lesanics, and Decastro (2015), “The Federation of State Medical Boards
undertook the development of model guidelines aimed at encouraging state medical
boards, its licensees, and other health care regulatory agencies to adopt policies
promoting adequate treatment of patients using opioids when appropriate” (p. E307). This
policy resulted in increased availability of opioids. Yet, empirical evidence suggests that
the amount of pain that Americans report has not changed (CDC, 2016a; HHS, 2016).
This discrepancy between opioid use and perceived effectiveness is an indication that
clinicians are overprescribing.
Overprescribing results in more opioids available for abuse and consequently
more deaths due to overdose (Agarin et al., 2015). According to CDC (2016b), “Health
care providers wrote 259 million prescriptions for opioid pain medications in, 2012. That
is enough for every American adult to have a vial of pills” (p. 1). Statistics indicate that,
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as the availability and use of opioids analgesics increased, so did the number of fatalities
(Agarin et al., 2015; CDC, 2011). This finding indicates that far too many opioids are
available for public consumption (Agarin et al., 2015). Hence, prevention of opioidrelated health disorders and addiction can prove the most appropriate strategy for
effecting change (CDC, 2016a).
The CDC responded to this epidemic with Opioid Prescribing Recommendations
(CDC, 2016b). These guidelines were developed using the GRADE systematic review of
the best evidence available. The GRADE (Grading of Recommendations Assessment,
Development, and Evaluation) system was informed by the recommendations from
leading experts in the pain management field (CDC, 2016a). Implementing the new CDC
guidelines has the potential to mitigate the growing prevalence of overprescribing, thus
avoiding the potential for abuse, dependence, disorders, addiction, and overdose.
Role of the DNP Student
The role of the doctorally prepared nurse student in this project pertained to
evaluating this quality improvement program for primary care practice. For this project,
the DNP student was assigned to evaluate a practice-focused program that had a specific
practice application-oriented goal (AACN, 2006). As an evolving expert in the science
practice application, the DNP student selected and evaluated measures of appropriate
indices for this quality improvement program. It was determined that the program
implemented for the improvement of patient care delivery and patient outcomes met its
practical objectives. The DNP student sought to provide leadership for the staff members
working in other disciplines in the evaluation of a systematic approach to address this
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professional challenge (AACN, 2006). This included collaborating with experts and
practitioners in other disciplines to bring about appropriate conclusion (AACN, 2006). It
also involved directing staff members working in other disciplines to assist in the
evaluation process and incorporate their expertise. This type of leadership acknowledged
the value in other disciplines in terms of perspective, expertise, and skills these
individuals contributed to the problem solving process (Joshi, 2014).
This project required data collection and analysis from the EHR, which was
conducted in collaboration with the Quality Improvement Manager (AHRQ, 2014). The
DNP student provided the QI Manager with the appropriate health IT methodology to
collect the data necessary to accurately measure opioid prescribing rates. This data was
needed to retrospectively evaluate the baseline prescribing rates prior to the program
implementation, as well as the prescribing rates recorded after the program was
implemented. The data was analyzed to determine the effectiveness of the program in
curtaining prescribing rates.
The data was retrieved from the medication registry within the EHR. This
database allows for the retrieval of the number of opioids being prescribed at any given
date or within a date range. This approach ensured greater accuracy in evaluating the
prescribing rates (Joshi, 2014). The value of this program evaluation project relates to the
ability to replicate the program should it be determined effective (Grove et al., 2014). In
addition, this program could serve as a blueprint to effect organizational change within
multiple primary care practices.
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Summary
This project sought to evaluate a program implemented to curtail the iatrogenic
opioid overprescribing practices in primary care via the medication registry of the EHR.
The program was based on Lewin’s conceptual model to operationalize the change in
three phases. The CDC (2016a) clinical guidelines provided the structure for the program.
The aim was to determine whether this evidence-based project has achieved the set
objective of curtailing prescribing rates. This was measured by evaluating the EHR data
to determine whether any changes to prescribing were noted following program
implementation.
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Section 3: Collection and Analysis of Evidence
Introduction
It remains to be determined if adherence to the CDC (2016) evidence-based
guidelines can curtail opioid overprescribing in primary care. The standard of care that
allowed clinicians to prescribe opioids based on subjective reports of pain has resulted in
poor patient outcomes (CDC, 2016; HHS, 2016; Time Inc., 2016). Since the initiation of
this standard set by the NPC & JCAHO in 2001, a 200% increase in opioid-related deaths
has been recorded (CDC, 2015b, 2015d; HHS, 2016; Manchikanti et al., 2012; Time Inc.,
2016). PCPs are the leading prescribers of opioids for chronic pain, yet few PCPs follow
standard practice guidelines regarding assessment and monitoring (Cheatle et al., 2014;
Lasser et al., 2015). The effectiveness of adhering to CDC 2016 Clinical Guidelines for
Opioid Prescribing in curtailing the current prescribing rates among PCPs has not been
assessed to date (CDC, 2016; Lowe, 2016). It also remained to be ascertained if
application of these guidelines would improve patient outcomes in terms of dependence,
addiction, abuse, and deaths (CDC, 2016). The development and use of a program to
improve patient outcome by curtailing opioid prescribing in primary care was needed.
An advantage of implementing this program at the selected primary care practice
stemmed from the staff’s collaborative approach and willingness to counter the practice
problem through implementation of evidence-based solutions. In this collaborative
interaction, each party’s concerns and perspectives were valued and addressed, and
different perspectives were coalesced or overcome (Thomas, 1976). In addition, the
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collaborative was favorable toward having an advanced practice nurse take on a
leadership role in the planning and implementation of systematic changes in health care
for better patient outcomes (AACN, 2006). Although the value of the other disciplines
cannot be underestimated, the overall objective of this project was to assert nursing
leadership to improve patient and societal health. It served to further provide evidence of
the essential role of nursing staff in health care quality improvement (Joshi, 2014).
The chief executive officer, medical director, risk manager, and quality
improvement manager endorsed support for the implementation of an evidence-based and
recently partially legislated opioid curtailment program (AIA, 2016). The
interdisciplinary collaboration was a prudent strategy for positive outcomes in health care
(Joshi, 2014; World Health Organization, 1999). By addressing the practice problem
through evidence-based guidelines, providers and all stakeholders improved patient
safety and health care delivery (Vega & Bernard, 2015). The initiative put the patient at
the center of the health care team’s focus and allowed all health professionals, with the
patient, to collaboratively provide input, be part of the decision making, and improve
outcomes (Vega & Bernard, 2015). Again, the interdisciplinary collaboration assisted
with the logistics of the program as well as enhancing organizational performance
(Institute of Medicine, 2015). In the remaining sections of this project, I will provide an
overview of the opioid overprescribing epidemic, the multidisciplinary program for
countering the problem, and a system to evaluate the effectiveness of the program. I will
detail the collection and analysis of the evidence in the next segment.
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Practice-Focused Questions
The previous opioid prescribing standard has resulted in an increase in opioidrelated disorders and fatalities (Agarin et al., 2015; CDC, 2015b, 2015d, 2016a; HHS,
2016; Manchikanti et al., 2012). Efforts to increase opioid use and a campaign touting the
alleged under-treatment of pain continue to be significant factors in the escalation of this
nation-wide problem (Agarin et al., 2015, NPC, 2001). I sought to determine if the
application of the CDC Clinical Guidelines for Opioid Prescribing (CDC, 2016) would
curtail primary care provider prescribing rates. These clinical guidelines aimed to
specifically address the overprescribing practices by providers, which have resulted in the
current epidemic in the health care setting. Although it remained to be determined
whether the implementation of the guidelines would be effective in curtailing opioid
prescribing, it was clear that the old prescribing patterns were too harmful to continue
(Aragrin et al., 2015; CDC, 2011, 2016b).
According to the AIA (2016),
California has taken an important step in preventing prescription drug and opioid
abuse by passing SB 482 into law. The CURES database will be critical to helping
doctors prescribe medication responsibly and appropriately given each patient's
medical history. We applaud the legislature and Governor Brown for ensuring
patient and public safety by passing this life saving measure. (p. 1).
This mandated component of the CDC guidelines provided impetus for clinicians
to adhere to and give consideration to the recommendations.

28

The purpose of this scholarly project was to evaluate a program developed and
implemented to alter the current practice gap of overprescribing in a primary care
practice in central California. This intervention was implemented in the form of a
systematic quality improvement program using multidisciplinary approach to curtail
overprescribing. The terms physician, clinician,” nurse practitioner, and physician
assistant are used interchangeably in the following discussions, as they all relate to PCPs.
Definitions
The key terms for this project include overprescribing, primary care
provider/clinician, patient, curtail, and opioids. For the purposes of the project,
overprescribing refers to “the unnecessary use of drugs (to prescribe excessive or
unnecessary medication that is not beneficial for patients)” (Rambhade, Chakarborty,
Shrivastava, Patil, & Rambhade, 2012, p. 68). The term “primary care provider” refers
to “clinicians involved in the provision of integrated, accessible health care services by
clinicians who are accountable for addressing a large majority of personal health care
needs, developing a sustained partnership with patients, and practicing in the context of
family and community” (Rambhade et al., 2012, p. 68). The term “clinician” or
“provider” refers to “an individual who uses a recognized scientific knowledge base and
has the authority to direct the delivery of personal health services to patients” (Rambhade
et al., 2012, p. 68). The term “patient” refers to “an individual who interacts with a
clinician either because of illness or for health promotion and disease prevention”
(Rambhade et al., 2012, p. 68). The term “opioid” pertains to “any morphine-like
synthetic narcotic that produces the same effects as drugs derived from the opium poppy
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(opiates), such as pain relief, sedation, constipation and respiratory depression” (Gale
Encyclopedia of Medicine, 2016, p.1). Finally, “curtail” is defined as “to make less by or
as if by cutting off or away some part” (Merriam-Webster, 2016, p.1).
Exclusions
Patients with a cancer diagnosis or terminal illness were not included in either the
data collection for the program or the project. Patients in hospice care were also excluded
from the data collection, as were patients receiving opioids from providers (pain
management) outside of the primary care practice.
Inclusions
Patients receiving opioid agonists were included in the data collection for the
project and the program. All providers in the primary care clinic—i.e., primary care
physicians, nurse practitioners, physician’s assistants, internal medicine physicians, and
doctors of osteopathic medicine—were included in both the program and the project.
Sources of Evidence
To evaluate the effectiveness of this program, specific practice-related data were
collected. The participants for the data collection for this project were the Quality
Improvement Manager because of her role within the organization (AHRQ, 2014). The
QI Manager is expert in data retrieval and collection (AHRQ, 2014). Data is the
cornerstone of Quality Improvement, as according to HRSA (2016), “It is used to
describe how well current systems are working; what happens when changes are applied
and to document successful performance” (p.1).
Protections
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This project proposal was approved by the Walden Internal Review Board (IRB)
and the IRB approval number for this study is 02-06-17-0588593. According to Grove et
al. (2014), the participants in the project were protected according to the ethical principle
of beneficence. In addition, no provider names were associated with the statistical data
collected. The providers were protected from harm, as overall group prescribing rates
were obtained and no individual PCPs were associated with the data. This project was
conducted as an organizational quality improvement project. All data was provided by
the organization's Quality Improvement Manager at the direction of the doctoral student.
Procedures
The QI Manager took on the task of data collection from the EHR under the
direction of the DNP student. The Quality Improvement Manager’s first task was to
extrapolate data regarding the total number of opioid prescriptions being written prior to
the intervention program. The de-identified data was extrapolated retrospectively from
the medication prescriptions registry within the EHRs. The EHR has the ability to capture
data related to the number of opioid prescriptions being written within the primary care
practice at any given time. This data allowed the researcher to arrive at the exact number
of patients receiving opioids at any given point prior to and following program
implementation. This first measurement served as the baseline data set for the DNP
project.
The primary care practice staff, comprising of family practice physicians, internal
medicine physicians, physician’s assistants, and family practice nurse practitioners, had
their prescribing rates evaluated retrospectively. The rate represented prescribing rates
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prior to the intervention of the program and 5 months prior to the release of the CDC
(2016a) guidelines. After this number was obtained, an additional measurement of the
numbers of patients being prescribed opioids 5 months after the introduction of the
program was obtained. The difference in these two rates determined the effectiveness of
the program.
Opioids are natural or synthetic chemicals that bind to receptors in brain or body
(HHS, 2016). Common opioids include heroin and prescription drugs, such as
oxycodone, hydrocodone, and fentanyl (HHS, 2016). The list of opioids for data
collection included hydrocodone, oxycodone, hydromorphone, and fentanyl, as well as
other schedule II opioid agonists in the EHR. The prescribing rates for opioid agonists
were captured when the data was retrieved for both instances.
Analysis and Synthesis
The retrospective point in time data technique served as the data collection
method for comparison purposes. The first set of data was collected on May 1, 2015, five
months prior to the initiation CDC clinical guidelines. The second set of data was
collected on December 19, 2016, five months after the program was introduced. The
comparison of the two data sets allowed the effectiveness of the intervention to be
measured (Grove, et al, 2013).
Additionally, for continuous quality improvement, the QI Manager was advised
by the Risk Manager to obtain the prescribing rates monthly to provide continuous
monitoring of opioid prescribing rates for the practice following the project completion.
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These rates served to determine the effects of the project over time and to identify and
address changes in prescribing patterns.
Assessment of Program Implementation
To assess provider use of the guidelines within the program, the QI Manager
assisted in peer review. This assessment was associated with the program and was not a
part of the evaluation project. Each month, the QI Manager was to select five EHRs
encounters per provider for peer review. This represented a sampling of the provider
EHRs and included those for patients which are currently being prescribed opioids.
Providers had their information de-identified so as to preserve provider confidentiality.
Providers were assessed for the prescribing criteria contained within the peer review
template (See Figure 4). The scores reflected the degree of compliance with the criteria,
whereby the score of 5 denoted full compliance, and 0 indicated non-compliance. The
findings were distributed to providers confidentially for quality improvement purposes,
while allowing each individual to discuss the results with the Quality Improvement
Team.
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Figure 4 PEER CHART
REVIEW
Today's Date:
Audited
Charts' #

Provider Review:
Please Review these Progress Notes on
the date of:

Description
Risk Assessment

1

2

History of Mental
Illness

3

History of Diversion

4

History of Overdose

Pain Contract

5

There is a pain contract accompanying

Drug Screen

6

Documented drug screen on chart.

7

Length of therapy and goals are
documented.

8

Results of cures report documented

Discussed
Length of
Therapy and
Goals
Cures Report

Date
Chart
#

Date
Chart
#

Date
Chart
#

Date
Chart
#

Questions

History of
Substance
Abuse

Provider has
indicated He/She
has assessed the
patient for
Risk Behaviors or
Conditions

Date
Chart
#

Reproduced from Primary Care Prescribing Criteria Centers for Disease Control, 2016 CDC Guideline
for prescribing opioids
for chronic pain. MMWR: United States. Accessed 12/1/2016
http://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm

The quality improvement team consisted of the Medical Director, the Quality
Improvement Manager, a Nurse Practitioner, and Risk Management. The team reviewed
the monthly prescribing rates along with the peer review findings. They examined the
results and discussed the findings. Providers who were non-compliant had the
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opportunity to present their barriers to compliance without fear of reprisal. They were
advised and coached to remove incentives to engage in negative behaviors (Understand
Just Culture, 2013). This approach was consistent with the Just Culture Model for
behavioral changes (Understand Just Culture, 2013). However, egregious errors in opioid
prescribing safety needed to be addressed by the team. These errors, having been
considered a conscious disregard to safety, have been determined to be reckless. This
behavior may result in punitive deterrents if determined appropriate by the organization
(Understand Just Culture, 2013). The collaborative effort of this team was expected to
alter these undesired behaviors. This quality improvement program resulted in increased
accountability for the providers making choices related to opioid prescribing practices.
Purpose of Data Collection and Analysis
The data obtained through peer review was analyzed to assess provider use of the
guidelines. The findings yielded indicated the extent to which the gap in practice was
bridged. To determine whether the guidelines are being implemented in the primary care
practice, there needed to be support to confirm their use. Peer review helped identify the
gap in practice, whereby providers are not adhering to the CDC primary care practice
guidelines (Cheatle et al., 2015; Lasser et al., 2014). Further, there needs to be ongoing
assessment to determine if the change is sustained or if providers have returned to old
prescribing standards. Ongoing assessment will be needed to ensure that the organization
continues to adhere to the process after the project ends (Joshi, 2014). The peer review
portion of the program is primarily a tool for the QI manager to determine whether
specific providers are adhering to the program policies and expectations.
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However, the data collected from the medication registry pertained to the actual
prescribing rates. This data relates to the project objective, which was to determine
whether the use of the guidelines is affecting prescribing rates. Providers were expected
to adhere to the CDC guidelines to alter the current system, which has led to poor
outcomes (CDC, 2016a). This approach was directed toward addressing guideline
adherence and prescribing rates. The goal of the program was to determine whether
prescribing rates can be curtailed by the use of the guidelines. In order for this to be
accurately evaluated, as a part of the assessment of prescribing rates, it was essential to
determine whether the guidelines are being applied. In other words, the aim was to align
what was believed to be happening from the actual practices (HRSA, 2016).
Summary
The data collected for the evaluation project allowed the previous and current
opioid prescribing rates to be evaluated and compared. For this purpose, the prescribing
rates were sourced from the practice’s EHR medication registry. The data related to
opioid agonists was captured in order determine prescribing rates prior to and following
program implementation. This source of information provided measures related to the
purpose of this project, which was to determine if the implementation of the program,
which uses the CDC clinical guidelines, would curtail prescribing rates in a primary care
setting. The retrospective data collection prior to and following program implementation
provided the evidence to determine the program’s effectiveness. It necessitated the
collection of data from the EHR opioid medication registry, which was deemed the most
appropriate method for meeting the purpose of the evaluation project (Joshi, 2014).
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The data collected for the primary care provider peer review reflected provider
compliance with the program. It allowed evaluation of provider adherence to key
components of the CDC (2016a) Clinical Guidelines for Opioid Prescribing. This
initiative helped to determine if prescribing behaviors have changed and whether the
change is being consistently maintained. This data was gathered for quality improvement
purposes and not for the purposes of the project.
This program has been implemented in two primary care locations. One of the
clinics is located in central California (practicum location) and the other in South Los
Angeles (work location). The practicum clinic consists of 10 PCPs averaging 2,300
patient visits per month, and the South Los Angeles Clinic Consists of 12 PCPs averaging
2,800 visits per month. The practicum location was used for the project’s retrospective
data collection related to the prescribing rates recorded in the EHR medication registry.
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Section 4: Findings and Recommendation
Introduction
The problem of overprescribing in primary care practice has resulted in poor
patient outcomes, including dependence, abuse, misuse, and death (CDC, 2016a; HHS,
2016). The problem is iatrogenic and needed to be addressed through practice changes
(CDC, 2016b). The current gap in practice results from an old faulty standard of practice
that did not adhere to the evidence-based CDC (2016a) guidelines. I sought to evaluate a
program developed to systematically address this gap by applying these guidelines in
primary care. The objective was to determine whether this program could curtail opioid
overprescribing practices in a primary care setting.
Exclusions
Patients with a cancer diagnosis or terminal illness were not included in the data
collection for the program or the project. Patients in hospice care were also excluded
from the data collection, as were patients who were receiving opioids from providers
outside of the primary care practice.
Inclusions
All primary care clinicians were included in the program and the project. For
these purposes, primary care physicians, nurse practitioners, internal medicine
physicians, and doctors of osteopathic medicine were included in the data collection. All
noncancer, nonpalliative care patients receiving Schedule II opioid agonists from a
primary care provider within the practicum site were included in the measurements.
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Methods and Findings for the Project
I collected the data required for the project retrospectively and was sourced from
the EHR medication registry. I accessed the medication registry to provide point in time
data indicating the number of patients actively being prescribed opioid agonists. This
included hydrocodone/norco, oxycodone/percocet, hydromorphone, oxymorphone, and
Fentanyl. I collected the first set of data on May 1, 2015, 5 months prior to the release of
the CDC (2016) clinical guidelines. I collected the second set of data on December 19,
2016, 5 months after the program was introduced (See Table 1).

Table 1
Active Totals for Premeasurement Dates and Postmeasurement

05-15-2015

1103

12-19-2016
646
________________________________________________________________________

Findings and Implications for the Project
As mentioned previously, I collected two sets of point in time data for the project
and compared the sets to assess the program’s effectiveness. I collected the first set of
data on May 1, 2015, 5 months prior to the introduction of the CDC clinical guidelines,
and obtained the second set of data on December 19, 2016, 5 months after initiating the
curtailment program. The retrospective data collected pertained to all patients who were
actively prescribed opioids at the primary care practice on those dates. Using a t test to
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examine differences between the two datasets, results revealed a 49.24% statistically
significant difference (p < .01) between the prescribing rates prior to and following
program completion, confirming its effectiveness.
DNP Project Data
Upon comparing the two measurements, a significant and a much greater than
anticipated decrease (from 1,068 patients to 646) in the number of patients receiving
opioids was noted. Owing to this dramatic decrease in the number of patients receiving
opioids, the quality improvement and risk managers retrieved records for additional dates
to verify the trend. The trends for prescribing rates are listed below.

Table 2
Trend for Opioid Prescribing Rate
__________________________________________________________________
Dates

Patients Receiving Opioids

07-12-2015

1068

08-23-2016

821

09-29-2016

738

10-11-2016

722

11-15-2016

594

12-19-2016
646
_________________________________________________________________
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Recommendations for the Project
After reviewing and analyzing the data for the project that the project team
recommended that providers be surveyed to determine the greatest influence in curtailing
prescribing rates. Providers should be allowed to share which parts of the program were
beneficial and which parts of the program were least helpful in guiding their clinical
decision making (Understanding Just Culture, 2013). In addition, we advised that the QI
manager continue to retrieve the data from the medication registry monthly to monitor
providers’ prescribing rates as a means of identifying changes (if any) in prescribing
trends (Heath Resources & Services Administration (HRSA), 2016). This will allow QI
and risk management to identify the most effective portions of the program and to
respond to problems early on before they present major challenges for the organization.
Findings and Implications for the Program
The data for the program was collected through peer review. Five charts per
provider were audited for the five criteria in the peer review template. One point was
awarded for each of the five criteria or elements present within the chart. Thus, a provider
could score a maximum of 25 points.
After a score was obtained for each provider, the information was confidentially
disseminated. The providers subsequently met with the program coordinator to discuss
the findings in a group setting, ask questions regarding the results, and discuss any
concerns related to the program. In the initial peer review, the findings were discussed in
a group setting with the understanding that future peer reviews will involve the QI
Manager, Risk Manager, and the Medical Director.
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The findings indicated that the highest points among all providers were received
for having pain contracts, PDMP or CURES reports, and risk assessments in that order.
The pain contract was by far the most consistent item found in the EHRs of patients
receiving opioids. The lowest scores were associated with discussing the length of
therapy, the goals of therapy, and drug screens in that order. Providers in general did not
discuss the goals of pain management or the expected length of treatment with their
patients. This finding was not surprising, as according to Chou (2016) clinicians as a rule
do not continue most medications (with the exception of opioids) that are not proving to
be effective in addressing a problem.
Recommendations for the Program
In addition to project data, program data was also collected through peer review in
the form of chart audits. The charts selected for the peer review belonged to patients who
were currently receiving an opioid agonist. The initial peer review was conducted four
months after the initiation of the program. This initiative was a part of the quality
improvement assessment. The de-identified findings of the peer review were discussed
with the staff.
Upon reviewing the findings of the program, it was recommended that the QI
Manager continue peer review quarterly. This will ensure that providers improve on their
compliance in this area and do not return to the old standard of practice (Joshi, 2014).
Performing this exercise going forward will serve as a reminder to continue adherence to
the evidence-based guidelines. The refreezing portion of the program will require
continual evaluation. Additionally, ongoing monitoring will serve as continuous quality
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improvement for the organization (Joshi, 2014). It is further recommended that providers
document the criteria in consistent locations within the chart. This quality improvement
recommendation will facilitate the retrieval of the required information for the reviewer.
It is further recommended that the project be replicated in other primary care
settings (Joshi, 2014). It has been established that the primary care program can curtail
prescribing rates in the primary care setting. Therefore, the benefits of replicating this
program include potentially decreasing the negative outcomes for additional primary care
patients while providing evidence-based guidelines for clinical decision making in other
practices. The purpose benefit of quality improvement programs can be translated to
other similar settings (Joshi, 2014).
Strengths and Limitations
The strength of this project rests within its ability to assess and validate a program
with the potential to curtail in prescribing patterns in primary care. This project, which
evaluates a quality improvement program, was developed according to a problem solving
evaluation design as outlined in Grove et al (2013). The data collected for the evaluation
project served to evaluate pre and post intervention opioid prescribing rates as well as
validate the effectiveness of the program. It identified differences pre and post
intervention prescribing rates through EHRs medication registry. The sources of this data
were deemed most appropriate for the purposes of the evaluation project (Joshi, 2014). It
evaluated the program’s ability to produce a positive result in terms of curtailing
prescribing rates.
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The rigor and stringent controls were not in place for the evaluation of the
effectiveness of the treatment or intervention in this project (Grove, et al, 2013). The
project involved conducting an evaluation of a program to apply a new standard of care
to address a serious health care issue (Grove, et al, 2013). It was conducted in a usual real
world clinical primary care environment to evaluate an intervention.
Strengths and Limitations of the Program
The program data reflects provider compliance with the program only in part. It
assessed for provider adherence to key components of the CDC (2016) clinical guidelines
for opioid prescribing. It has helped to determine that provider prescribing behaviors
have changed however many components of the program were not totally adhered to. The
findings indicated that the components of the peer review are not being consistently
maintained even though prescribing rates declined. This data was for program quality
improvement purposes and not for the purposes of the project.
The process was tedious as many of the providers were not consistent in their
placement of the pertinent data within the EHR. This process has helped the organization
to realize that they need better consistency in documenting and document placement
within the EHR. This was an incidental quality improvement finding to be discussed with
the stakeholders and providers in the final PowerPoint presentation (Joshi, 2014).
Summary
The results of this project indicated that the program is worth the investments in
implementation. Although there are additional costs in terms of provider responsibilities
and administrative time, it may be well worth the investment. Considering the current
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mortality and morbidity rates, societal costs and lack of provider confidence in
prescribing the program has definite value (Birnbaum et al., 2011; CDC, 2016a, 2016b).
Ultimately, because the program has the ability to reduce patient and organizational risks
associated with opioid overprescribing and opioid disorders the program holds definite
value. The evidence of its significance is apparent in the lowered prescribing rates among
the target population of PCPs (CDC, 2016a).
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Section 5: Dissemination Plan
Organization Dissemination
To disseminate the project findings to the target organization, I presented a final
PowerPoint presentation (Joshi, 2014). The primary care staff, the risk manager, quality
improvement manager and all stakeholders viewed the PowerPoint presentation. The
presentation included the program findings and the project findings. This vehicle was an
efficient method of disseminating the information while providing a forum to allow for
questions and feedback (Bartsch & Cobern, 2003). This method also seemed appropriate
considering these meetings were regularly scheduled for quality improvement purposes.
The program policy and the program peer review guidelines will remain at the
facility with risk management and quality improvement to continue the program goals.
Nursing Dissemination
I will utilize a variety of methods to disseminate the project findings. I will send
the final project to AANP to determine interest in the subject matter. I contact other
nursing journals, as well as Medscape, to ascertain whether or not topic is of interest to
their subscribers. I will solicit interest in presenting for the Family Nurse Practitioner
Students at the University of California at Los Angeles. I am a clinical instructor for the
university and an associate instructor allowing for the opportunity lecture on the topic of
opioid use in primary care. I believe the project content will be valuable in providing
clinical direction for new providers.
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Some of the most effective methods of dissemination in terms of turning the tide
of opioid prescribing are through educational programs. That method would provide an
evidence-based foundation for current prescribing standards and their implementation.
Other methods include presentations at conferences for PCPs, primary care practice
updates, and university pharmacology courses as well as online presentations. The
aforementioned vehicles for dissemination could serve as efficient methods to
disseminate the information to advanced practice nurses as well as the primary care
community in general.
Analysis of Self
Throughout the program and project, my focus was on the ability of the
program to curtail primary care provider opioid prescribing rates. I found myself so
focused on the prescribing rates that I lost sight of the patients at times. In many
instances,
the medication was inappropriately prescribed. However there are times when opioid
medications are needed and this perspective should be factored into prospective future
programs. I have to be cognizant of the need for variations in clinical decision making
when warranted. It is my desire to continue to take on a leadership role in addressing
this provider and societal problem through evidence-based practice. To achieve this goal,
I will need to remain adaptable as well as focused and intentional.
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Summary
In this project, I evaluated an evidence-based quality improvement program to
curtail overprescribing in primary care practice. The program incorporated the new CDC
(2016a) clinical guidelines developed expressly for PCPs. After measuring prescribing
rates prior to the introductions of the guidelines and postprogram interventions, it was
determined that the program was able to curtail overprescribing in primary care practice
with a 49.24% change. As a result of these findings, it is the organization’s expectation
that this program will be replicated in additional primary care practice offices within this
organization.
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Appendix A: Peer Review Guidelines
American Association of Family Practice Peer Review Guidelines
For the purposes of this program, the terms Clinician, physician and provider will
be used interchangeably due to the participation of Mid-Level Providers (Nurse
Practitioners and Physician Assistants). According to the American Association of
Family Practice (AAFP, 2014) guidelines, in order for a meaningful peer review to take
place, adherence to the following criteria is essential:
1. The primary goal of peer review should reflect enhancing the quality of patient
care. Nonetheless, peer review will increasingly address issues of value-driven
care. Physicians/Providers should initiate and lead these conversations.
2. Clinical policies for patient care should be established by practicing
physicians/providers based upon the best patient-oriented evidence available,
balanced with sensitivity to local needs and expectations (See figure 5).
3. Physician departure from clinical policies (e.g., clinical guidelines) should not be
interpreted as a prior breach of good medical practice. Patient preference,
availability of services, and assessment of individual risks vs. benefits may
substantially influence management. Physicians/Providers should have access to
the full rationale of peer decisions and opportunity for rebuttal if a negative
conclusion is reached.
4. Peer review should include assessment of the quality of care rendered. It should
be performed by a physician/provider holding qualifications similar to those of
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the physician/provider being reviewed to ensure objectivity and
comprehensiveness of assessment.
5. Criteria for care (e.g., hospital admission, transfer, or alternative care site
delivery) should reflect severity of illness, social factors, caregiver burden, access
to services, and the particular circumstances of each patient.
6. Utilization review provided by a physician/provider should be considered the
most valid determinant of the correct diagnostic category. Physician/Provider
peers should determine the appropriateness of care, while recognizing and
assessing the complexity of factors influencing decision-making.
7. The peer review should be aimed at the improvement of patient care through
physician/provider education and health system enhancements. Those performing
the peer review should seek to identify potential systematic improvements that the
organization could implement to reduce the potential mistakes or adverse events
in the future.
8. Due to the need to safeguard public interest, peer review by medical staff, medical
societies, medical groups, health plans, and other entities should be confidential,
protected, and not subject to disclosure or discovery. Nonetheless, the evidence
and clinical decision-making criteria used in developing peer review decisions
should be transparent and open to scrutiny. Those subject to peer review should
be given the opportunity to provide further information and rebuttal to the peer
review outcomes.
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Appendix B: Opioid Prescribing Policy
Title:
Safe Opioid Prescribing in Primary Care
Section: Medications
Number:
Effective Date: October 2016
Reviewed Dates: September 2016
Revised Dates:
Manager Signature
Board Approval:

1.0 Purpose:
To address the issue of pain treatment in primary care practice. Considering the
increased incidence of opioid related deaths, abuse, disorders, and diversion (CDC, 2016)
all schedule 2 drugs will require that steps be followed to insure safe opioid/controlled
substance prescribing.
2.0 Policy:
This policy will provide guidelines for prescribing schedule 2 drugs at UMMA Clinic.
Opioids are not to be prescribed as the first-line treatment for chronic pain. Patients
determined to be opioid dependent, addicted or with opioid disorder should be
appropriately referred for behavioral health and/or addiction counseling services.
2.1 This policy will provide guidelines for prescribing schedule 2 drugs at UMMA
Clinic. Opioids are not to be prescribed as the first-line treatment for chronic pain.
3.0 Supportive Data:
4.0 Equipment and Forms:
4.1 Pain Contract (see attached exhibit)
5.0 Procedure:
5.1. A full pain inventory will be obtained on the initial visit. Patient will be assessed for
risk factors for drug abuse. These risk factor include, history of abuse, history of
overdose, history of diversion, and consideration of mental illnesses.
5.2. A CURES report should be obtained on all patients before prescribing opioids for
the treatment of pain (Reports may be scanned or downloaded to the patient chart).
5.3. A pain contract will be signed and agreed to by the patient receiving opioid
treatment.
5.4. An initial urine drug screen is to be obtained prior to initiating opioid treatment and
periodic drug screens should be obtain to evaluated for multi-substance use or diversion.
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5.5. The length of treatment, the goals of treatment, and the addictive nature of the
medication is to be disclosed to the patient prior to initiating treatment.
5.6. All patients requiring opioids beyond a 3-month period, or the normal period for
expected healing should strongly be considered for referral to pain management.
5.7. The simultaneous prescription of benzodiazepines and opioids should be avoided.
6.0 Documentation:
7.0 References and Resources:
7.1 Centers for Disease Control, (2016). CDC Guidelines for prescribing opioids for
chronic pain. MMWR: United States. Retrieved from
http://www.cdc.gov/mmwr/volumes /65rr/rr6501el.htm
7.2 CURES (Controlled Substance Utilization Review and Evaluation System) website:
https://oag.ca.gov/cures
7.3 Medical Board of California Prescriber Guidelines for Substances for Pain, (2016).
Comparison of Prescribing Guidelines.
Created by: Glenda Le Flore, RN, MSN, PHN, FNP-c
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Appendix C: PowerPoint Presentation
PowerPoint Presentation
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